TL;DR
Get oils, diffusers and self-care delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
A paper in The Lancet Healthy Longevity argues that sarcopenia and mobility loss in older adults should be understood as problems involving the aging motor system, including the brain, nerves and muscles. The authors propose changes to research and assessment, but say new tests have not yet been shown to outperform current screening or improve outcomes.
A paper published in The Lancet Healthy Longevity argues that weakness and mobility loss in older adults cannot be explained by muscle loss alone, and proposes treating sarcopenia as a problem of the aging motor system. The authors say the concept could change how clinicians assess declining movement, but acknowledge that their proposed measures still need validation and have not been shown to improve patient outcomes.
Sarcopenia is a substantial decline in muscle strength, muscle mass and physical function associated with aging. Medical Xpress reports that it affects up to 29% of community-dwelling older adults, with higher rates among people in hospitals and residential care and among those with frailty or multiple health conditions. It is associated with disability and loss of independence.
The authors, led by Lucas B. R. Orssatto and colleagues, say diagnosis has already shifted toward measures such as grip strength, walking speed and chair stands, because these measures predict falls, disability and death better than muscle mass does. They argue that the explanation has not kept pace: sarcopenia is still commonly described as a muscle disease, even though muscle loss accounts for only a modest share of the decline in strength seen with age.
The paper says movement depends on a wider system, from the brain and spinal cord to nerves and muscle. Age-related changes to planning, nerve signals, balance and position sense may all affect function. The authors propose that assessment could pay closer attention to how quickly someone stands, steadiness during sustained effort, hand dexterity and walking while talking. They also suggest reviewing medicines that may blunt motor drive, including sedatives and anticholinergic drugs.
Rethinking How Clinicians Assess Weakness
The proposed reframing matters because treatment and research have often focused on increasing muscle mass, while the outcomes that shape daily life are strength, balance and the ability to move. The authors point to disappointing functional gains from some approaches that build muscle and to evidence that exercise can improve strength and mobility even when measurable muscle mass does not change.
Falls show the potential consequences of mobility decline. Medical Xpress reports 253,800 fall-related hospitalizations in Australia in 2024–25, and 6,722 Australians died following a fall in the preceding year. It also cites an estimated A$5.4 billion in health-system costs from fall injuries. These figures describe the scale of falls, but do not establish that the proposed motor-system approach would prevent them.
If future studies validate practical assessments, clinicians may be better able to identify whether a person’s weakness reflects muscle loss, impaired nerve function, medication effects or a combination. That could support more targeted care, but the paper presents this as a direction for research, not a proven improvement in diagnosis or treatment.
Products Worth Considering
Withings Sleep Under-Mattress Sleep Tracking Pad
BowFlex Results Series SelectTech 552 Adjustable Dumbbell
Oral-B iO Series 3 Rechargeable Electric Toothbrush for Adults, Black, with 2 Brush Heads and Travel Case
As an affiliate, we earn on qualifying purchases.
From Muscle Mass to Movement
The clinical definition of sarcopenia has evolved. Rather than relying mainly on muscle mass, current diagnostic approaches emphasize function-related measures such as strength and gait speed. The authors’ argument is that this change in measurement should prompt a broader account of what causes functional decline.
The discussion comes as Australian primary care is being asked to address poor muscle health. Earlier in 2026, the Australian Journal of General Practice published a proposed algorithm for screening, assessing and managing it in primary care. The new paper, titled “Reframing sarcopenia as a disease of the ageing motor system,” calls for international groups that set diagnostic criteria to consider a broader framework.
The authors propose a five-point agenda for those working groups, as described in the report, and call for practical tests, staged clinical guidance and trials that measure nerve as well as muscle. The paper does not provide evidence that these proposed changes are already part of standard diagnostic criteria.
“Nobody has yet shown that these measures beat existing screens, either on outcomes or on cost.”
— The authors, as summarized by Medical Xpress
Evidence Needed Before Practice Changes
The paper proposes a framework; it does not establish that motor-system assessments are more accurate, cost-effective or beneficial than current screening. The authors say no evidence has yet shown that the suggested measures improve outcomes or outperform existing screens. They also note that access to neuromuscular expertise is uneven in primary care.
It remains unclear which specific tests would be reliable and practical across different care settings, whether they would change treatment decisions, and whether any resulting changes would reduce falls or preserve independence. The source report does not give trial results demonstrating that medication review or the proposed assessment additions prevent mobility loss.
Validation and Updated Guidance
The authors call for research to validate practical clinical tests, guidance that supports a staged approach to assessment and trials that measure nerve function alongside muscle. International working groups responsible for sarcopenia diagnostic criteria are the intended audience for their proposed agenda.
For now, the paper should be read as a call to broaden research and clinical attention, not as a replacement for established screening. The next evidence to watch for is whether studies can show that the proposed measures are usable in primary care and improve outcomes that matter to older adults, including mobility and independence.
Key Questions
What does the paper mean by the motor system?
It refers to the systems involved in producing movement, including the brain, spinal cord, nerves and muscles, as well as functions such as balance and position sense.
Does this mean sarcopenia is no longer a muscle condition?
No. The authors argue that muscle loss is only part of the explanation for declining strength and function, and propose a broader framework. Their paper does not itself change formal diagnostic criteria.
What assessments do the authors suggest examining?
They suggest looking beyond whether someone can stand from a chair, including how quickly they rise, steadiness during effort, hand dexterity and walking while talking. These suggestions still require validation.
Have the proposed assessments been shown to prevent falls?
No such evidence is reported. The authors say the measures have not been shown to outperform existing screens on outcomes or cost, and call for further testing.
Source: medicalxpress.com
